RARE DISEASERESEARCH ATLAS

ORPHA:276432

Ogden syndrome

low confidenceDisorder

Also known as: Premature aging appearance-developmental delay-cardiac arrhythmia syndrome

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

837

Trials

0

Interventional, condition-specific

Researchers

1,395

Distinct authors in sample

Gene link

NAA10

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Ogden syndrome is a rare, genetic progeroid syndrome characterized by a variable including postnatal growth delay, severe global , , non-specific facies with aged appearance and cryptorchidism, as well as cardiac arrthymias and skeletal anomalies. Patients typically present with widely opened fontanels, mainly truncal , a waddling gait with of the extremities, small hands and feet, broad great toes, scoliosis and redundant skin with lack of subcutaneous fat.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

N-terminal acetyltransferase deficiency · OGDNS · Ogden syndrome, X-linked recessive, X-linked dominant · premature ageing appearance-developmental delay-cardiac arrhythmia syndrome · premature aging appearance-developmental delay-cardiac arrhythmia syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — NAA10

  2. LiteraturePresent

    837 matched papers (635 in last 10 years) Source

  3. Phenotype characterisedPresent

    170 HPO annotations (e.g. Scoliosis; Postnatal growth retardation; Aplasia/Hypoplasia of the eyebrow) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (NAA10).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

170

Associated phenotypes · MONDO:0010457

  • Scoliosis
  • Postnatal growth retardation
  • Aplasia/Hypoplasia of the eyebrow
  • Cryptorchidism
  • Proptosis

Showing 5 of 170 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

837

837 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

837 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

635 in the last 10 years · low confidence

Phrase hits: 185 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,395

Distinct author names in 185 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Lyon GJ35 papers · 2026

    Department of Human Genetics and George A. Jervis Clinic, Institute for Basic Research in Developmental Disabilities (IBR), Staten Island, NY, USA.

    Papers in Europe PMC
  2. 02
    Arnesen T30 papers · 2025

    Department of Molecular Biology, University of Bergen, Bergen, Norway.

    Papers in Europe PMC
  3. 03
    Marchi E20 papers · 2026

    Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States.

    Papers in Europe PMC
  4. 04
    Makwana R10 papers · 2026

    Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.

    Papers in Europe PMC
  5. 05
    Støve SI10 papers · 2018

    Department of Molecular Biology, University of Bergen, 5020 Bergen, Norway; Department of Surgery, Haukeland University Hospital, 5021 Bergen, Norway.

    Papers in Europe PMC
  6. 06
    McTiernan N9 papers · 2025

    Department of Biomedicine, University of Bergen, Bergen, Norway.

    Papers in Europe PMC
  7. 07
    Marmorstein R8 papers · 2023

    Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA. marmor@upenn.edu.

    Papers in Europe PMC
  8. 08
    Patel R8 papers · 2026

    Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.

    Papers in Europe PMC
  9. 09
    Wang K7 papers · 2023

    Institute for Genomic Medicine, Utah Foundation for Biomedical Research (UFBR), Salt Lake City, UT 84106, USA ; Zilkha Neurogenetic Institute, Department of Psychiatry and Preventive Medicine, University of Southern California, Los Angeles, CA 90089, USA.

    Papers in Europe PMC
  10. 10
    Aksnes H6 papers · 2021

    From the Department of Molecular Biology, University of Bergen, N-5020 Bergen.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Ogden syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Ogden syndrome" OR "Premature aging appearance-developmental delay-cardiac arrhythmia syndrome" OR "N-terminal acetyltransferase deficiency" OR "OGDNS" OR "Ogden syndrome, X-linked recessive, X-linked dominant" OR "premature ageing appearance-developmental delay-cardiac arrhythmia syndrome") OR (MESH:"N acetyltransferase deficiency") OR ("NAA10" OR "NAA10 syndrome" OR "NAA10-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: N acetyltransferase deficiency

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Ogden syndrome" OR "Premature aging appearance-developmental delay-cardiac arrhythmia syndrome" OR "N-terminal acetyltransferase deficiency" OR "OGDNS" OR "Ogden syndrome, X-linked recessive, X-linked dominant" OR "premature ageing appearance-developmental delay-cardiac arrhythmia syndrome" OR "N acetyltransferase deficiency"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (837) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T11:42:21.092Z